Factors that may help physicians determine when additional treatment is medically futile, and what physicians can do to encourage patients to explore more appropriate care options. Medical and ...
Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc [PH20]), a neonatal Fc receptor blocker, for the treatment of moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results